LKFT

Lakefront Biotherapeutics N.V.

53
Fundamentals68/ 100
Valuation50/ 100
Upside potential54/ 100
Risk potential14/ 100

LKFT's fundamentals are strong: revenue more than tripled and its operating margin went from −127% to 62%, though free cash flow turned negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.

LKFT Fundamentals

MetricStatus
Healthy
Strong
Weak
Strong

LKFT's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.

LKFT PE Valuation

CHEAPFAIREXPENSIVE1.4x2.8x4.3x5.7x
CHEAPFAIREXPENSIVE1.4x2.8x4.3x5.7x
LevelPEPriceVs current
Cheap3.2x$32.15-5.2%
Current3.4x$33.93—
Fair3.5x$35.61+5%
Expensive5.1x$51.37+51%

Historical ranges are pointers, not guarantees.

LKFT's PE is 3.4x, but its earnings don't support one, so it isn't a reliable read right now.

LKFT Forward outlook

MetricOutlook
--
Losses steady
Strong decline
--
Limited
Low

Analysts expect LKFT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.

LKFT Risk to reward

ScenarioChangePrice
Upside+17%$39.58
Downside-14%$29.07

Calculated from the latest close: $33.93 on Nov 12.

LKFT's one-year upside and downside scenarios are about the same size: +17% against −14%.

LKFT Earnings Per Share

Q3 2023: $-0.72Q4 2023: $-0.67Q4 2025: $5.41Q1 2026: $8.24Q2 2026: $10.05
Q3 2023: $-0.72Q4 2023: $-0.67Q4 2025: $5.41Q1 2026: $8.24Q2 2026: $10.05
QuarterTTM EPSYoY
Q4 2023-$0.67+$0.54
Q3 2023-$0.72-820%
Q2 2023-$0.79+$0.58

LKFT has returned to profit: it earned $10.05 per share over the past year, after losing money the year before.

LKFT Quarterly Revenue

Q3 2023: $133MQ4 2023: −$232MQ1 2024: $69MQ2 2024: $87MQ3 2024: $66MQ4 2024: $84MQ1 2025: $83MQ2 2025: $73MQ3 2025: $79MQ4 2025: $1BQ1 2026: $7MQ2 2026: $13M
Q3 2023: $133MQ4 2023: −$232MQ1 2024: $69MQ2 2024: $87MQ3 2024: $66MQ4 2024: $84MQ1 2025: $83MQ2 2025: $73MQ3 2025: $79MQ4 2025: $1BQ1 2026: $7MQ2 2026: $13M
QuarterRevenueYoY
Q2 2026$13.5M-81%
Q1 2026$7.2M-91%
Q4 2025$1B+1093%
Q3 2025$79.1M+19%
Q2 2025$72.5M-16%
Q1 2025$83.3M+20%
Q3 2024$66.5M-50%
Q2 2024$86.5M+30%

LKFT's revenue is growing: $13M last quarter, down 81% from the same quarter a year ago.

LKFT Free Cash Flow

Q3 2023: --Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: --Q4 2024: --Q1 2025: --Q2 2025: −$125MQ3 2025: −$73MQ4 2025: −$55MQ1 2026: −$92MQ2 2026: $0
Q3 2023: --Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: --Q4 2024: --Q1 2025: --Q2 2025: −$125MQ3 2025: −$73MQ4 2025: −$55MQ1 2026: −$92MQ2 2026: $0
QuarterFree cash flowYoY
Q2 2026$0+$125.5M
Q4 2020-$278.6M-108%
Q4 2019$3.7B+$3.8B
Q4 2018-$65.1M+$104.2M

LKFT has burned cash in most quarters: −$219M over the past year, against $3.2B the year before.

LKFT Total Shares

Q3 2023: 66MQ4 2023: 66MQ2 2024: 66MQ3 2024: 66MQ1 2025: 66MQ2 2025: 66MQ3 2025: 66MQ4 2025: 66MQ1 2026: 66MQ2 2026: 70M
Q3 2023: 66MQ4 2023: 66MQ2 2024: 66MQ3 2024: 66MQ1 2025: 66MQ2 2025: 66MQ3 2025: 66MQ4 2025: 66MQ1 2026: 66MQ2 2026: 70M
PeriodChange %Net change
Quarterly+6.4%+4.2M shares
1 year+6.4%+4.2M shares
3 years+6.5%+4.3M shares

LKFT has 70M diluted shares, up 6.4% from a year ago.

LKFT Net Leverage

Q4 2025: -0.3xQ1 2026: -0.1xQ2 2026: -0.2x
Q4 2025: -0.3xQ1 2026: -0.1xQ2 2026: -0.2x
QuarterNet LeverageStatus
Q2 2026-0.2xNet Cash
Q1 2026-0.1xNet Cash
Q4 2025-0.3xNet Cash

LKFT has more cash than debt.

LKFT Weekly Momentum

MetricValueStatus
RSI68.7Neutral
Stochastic87.8Overbought

LKFT's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).

LKFT PE vs Healthcare Sector

MetricLKFTSector medianRelative
PE3.4x26x87% below
PE %392910 pts above

LKFT is trading at 3.4x earnings, a 87% discount to the Healthcare sector's median of 26x, though its earnings don't support one.

LKFT Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$31.28.7% above
20 week MA$29.615% above
50 week MA$30.412% above
100 week MA$29.615% above
200 week MA$32.25.5% above

LKFT has climbed back above all five of its weekly moving averages, and it's now 5.5% above its 200-week average.

LKFT Yearly ROI

YearStart priceEnd priceROI
2020$209.4$99.3-53%
2021$99.3$55.9-44%
2022$55.9$42.2-25%
2023$42.2$40.7-3.7%
2024$40.7$27.3-33%
2025$27.3$33.0+21%
2026 YTD$33.0$33.9+2.7%

LKFT has finished lower in five of the last six years. It's up 2.7% so far in 2026.

Give your agent the market.

Get API key